Clinical trials: H Pylori Infection Eradication
H. Pylori Infection
Effect of Vitamin D on Drug Resistant Helicobacter Pylori (HP) Eradication Study
Background: Helicobacter pylori infection, which affects over 50% of the global population, is one of the most prevalent infectious diseases in the world. H.
- Trial name
- vDHp (NCT03142620)
- Testing
- Esomeprazole, Amoxicillin-Potassium Clavulanate Combination, Clarithromycin
- Where
- Hong Kong
- Volunteers
- 96 people
- Sponsor
- Chinese University of Hong Kong
Helicobacter Pylori Infection
Optimization of Vonoprazan-based Dual Therapy for Helicobacter Pylori
The purpose of this study was to evaluate the efficacy and safety of vonoprazan with different doses of amoxicillin for Helicobacter Pylori.
- Trial name
- NCT05649540
- Testing
- Vonoprazan, Amoxicillin
- Where
- 13 sites in China
- Volunteers
- 900 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Helicobacter Pylori Infection
A RCT of Triple Therapy With Proton Pump Inhibitor vs Vonoprazan for Helicobacter Pylori Gastritis
Helicobacter pylori (H. pylori) gastritis is a common bacterial infection among the elderly population. H. pylori infection causes chronic progressive gastric inflammation, peptic ulcer disease and gastric cancer.
- Trial name
- TRIVON (NCT03908619)
- Testing
- Omeprazole 20mg, Esomeprazole 20mg, Rabeprazole Sodium 20mg
- Where
- Singapore
- Volunteers
- 252 people
- Sponsor
- Changi General Hospital
Helicobacter Pylori Infection
The Epidemiology and Optimal Treatment of Helicobacter Pylori in Myanmar
This study aims to: 1. Determine the prevalence of Helicobacter infection in Myanmar (this would be the largest ever series in the country) 2.
- Trial name
- NCT04132479
- Testing
- Clarithromycin 500mg, Amoxicillin 500mg, Tinidazole 500mg
- Where
- Burma
- Volunteers
- 313 people
- Sponsor
- Kirby Institute
Helicobacter Pylori, Early Gastric Cancer
Helicobacter Pylori Infection Status and Pathological Features for Predicting Gastric Cancer Biological Behavior and Prognosis: A Real-World Observational Study
This multicenter retrospective and prospective real-world observational study will evaluate the relationship of Helicobacter pylori (H.
- Trial name
- NCT07724496
- Testing
- 13C-Urea Breath Test, Serum Helicobacter pylori Antibody Testing, Pathological Assessment of Gastric Tissue
- Where
- 3 sites in China
- Volunteers
- 1,500 people
- Sponsor
- Chinese PLA General Hospital
HELICOBACTER PYLORI INFECTIONS
Comparison of the Efficacies of Two Novel Dose Dual Therapies in the First-line Helicobacter Pylori Eradication
Background: The key factors for success are the maintenance of intragastric pH > 6 and the drug resistance to antibiotics. Proton pump inhibitor (PPI)-based high-dose dual therapy is a novel anti-Helicobacter pylori (H.
- Trial name
- Helicobacter (NCT06811207)
- Testing
- Vonoprazan, Esomeprazole 40mg, Amoxicillin
- Where
- Taiwan
- Volunteers
- 300 people
- Sponsor
- Chang Gung Memorial Hospital
H. Pylori Infection
Eradication of H. Pylori Therapy Individualized by the Mutation of 23S rRNA of H. Pylori
Patients infected with H. pylori are treated with the individualized regimen which is based on the mutation of 23S rRNA of H. pylori.
- Trial name
- EHR (NCT02761005)
- Testing
- Eradication of H. pylori
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Hamamatsu University
Helicobacter Pylori Infection
Safety, Efficacy of Pylera BID Dosing in Eradication of H. Pylori
The purpose of this study is to evaluate the effect of Pylera when given twice a day. Pylera approved treatment schedule is 3 pills taken 4 times daily, in addition to omeprazole given twice daily.
- Trial name
- NCT00712413
- Testing
- OBMT
- Where
- 3 sites in United States, Canada
- Sponsor
- Forest Laboratories
Helicobacter Pylori Infection, Gastrointestinal Dysbiosis
Bacillus Probiotics With Bismuth Quadruple Therapy for Helicobacter Pylori Infection
Helicobacter pylori (H. pylori) is a very common gastrointestinal disease that colonises the human gastric mucosa and is a primary risk factor for chronic gastritis, peptic ulcer disease, and gastric cancer.
- Conditions
- Helicobacter Pylori Infection, Gastrointestinal Dysbiosis, Antibiotic-associated Adverse Events
- Trial name
- NCT07827170
- Testing
- RO water, LiveSpo CLAUSY, LiveSpo DIA30
- Where
- Vietnam
- Volunteers
- 336 people
- Sponsor
- Anabio R&D
Helicobacter Pylori Infection
Genotypic Resistance Guided Versus Susceptibility Testing Guided Therapy for the First-line Eradication of H. Pylori
We aimed to (1) compare the efficacy of genotypic resistance guided sequential therapy vs. susceptibility testing guided therapy in the first-line therapy (2) assess the long term impact of eradication therapy on the antibiotic…
- Trial name
- NCT03556254
- Testing
- GGT, SGT
- Where
- Taiwan
- Volunteers
- 560 people
- Sponsor
- National Taiwan University Hospital
Helicobacter Pylori Infection
Tailored Vs. Empirical Helicobacter Pylori Infection Treatment
Helicobacter pylori (Hp) is a gram-negative bacterium that colonizes human gastric mucosa and is associated with chronic gastritis that can progress to severe complications such as peptic ulcer disease, gastric adenocarcinoma and…
- Trial name
- NCT06200779
- Testing
- Clarithromycin (mutations in the 23S rRNA gene, A2134G, A2142G and A2142C mutations) and levofloxacin resistance (mutations in the gyrA gene) PCR test, Empirically H. pylori eradication treatment with bismuth quadruple therapy (Pylera®), PPI, amoxicillin 1 g and clarithromycin 500 mg, twice daily, for 10 days
- Where
- Portugal
- Volunteers
- 160 people
- Sponsor
- Manuel Coelho da Rocha
Helicobacter Pylori Infection
Eradication of Helicobacter Pylori With a Lactobacillus Reuteri Strain Plus Proton Pump Inhibitor
Meta-analyses involving >4000 subjects with probiotics added to antimicrobial Helicobacter pylori eradication therapy in populations with antibiotic resistance have reported a mean increase in eradication rate of 12.2%.
- Trial name
- NCT03404440
- Testing
- L.Reuteri
- Where
- Italy
- Volunteers
- 56 people
- Sponsor
- University of Bari
Helicobacter Pylori Infection
Dysplasia Detection and Helicobacter Pylori Eradication
The investigators in the present study, aimed to assess the efficacy of both White-Light Endoscopy with High Resolution Endoscopy-Narrow-band imaging in the diagnosis of Premalignant Gastric Conditions, before and after…
- Trial name
- NCT03917836
- Testing
- endoscopy and histology
- Where
- Italy
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Helicobacter Pylori Infection
Lactobacillus Reuteri in Management of Helicobacter Pylori Infection in Dyspeptic Patients
Addition of L. reuteri to the standard triple therapy improves H. Pylori treatment outcomes.
- Trial name
- NCT01593592
- Testing
- Lactobacillus reuteri, Omeprazole, Amoxicillin
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Zagazig University
Helicobacter Pylori Infection
Effect of Dental Scaling on Helicobacter Pylori Eradication and Reinfection
Patients who had received H.pylori eradication treatment will be categorised as eradication and reinfection status and whether dental scaling has any influence on these results.
- Trial name
- Scaling and Hp (NCT01816269)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 300 people
- Sponsor
- Goztepe Training and Research Hospital
HELICOBACTER PYLORI INFECTIONS
Efficacy and Safety of Second-Line Helicobacter Pylori Eradication
Subjects with persistent H. pylori infection after first-line treatment failure receives either a 14-day PPI-based moxifloxacin triple regimen (esomeprazole, amoxicillin, and moxifloxacin) or a 14-day P-CAB-bismuth-containing…
- Trial name
- NCT07855497
- Testing
- P-CAB-BM quadruple regimen, Moxifloxacin triple regimen
- Where
- South Korea
- Volunteers
- 141 people
- Sponsor
- Seoul National University Bundang Hospital
Helicobacter Pylori Infection
Assesment of the Efficiency and Safety Helicobacter Pylori Therapy With or Without Saccharomyces Boulardii
This study assesses the effect of quadruple therapy for H. pylori, with the addition of probiotics Saccharomyces boulardii. In addition, he assesses whether this combination reduces the frequency of adverse effects of eradication…
- Trial name
- NCT03997279
- Testing
- Saccharomyces boulardii
- Volunteers
- 200 people
- Sponsor
- Clinical Centre of Serbia
H. Pylori Infection
The Efficacy of Sequential Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection - A Pilot Study
Helicobacter pylori infection has been shown to be associated with the development of gastric cancer and peptic ulcer diseases. Eradication of H. pylori infection could reduce the occurence or recurrence of these diseases.
- Trial name
- NCT00885417
- Testing
- Cravit-based sequential therapy
- Where
- Taiwan
- Volunteers
- 142 people
- Sponsor
- National Taiwan University Hospital
Helicobacter Pylori Infection, Peptic Ulcer Disease
Vonoprazan High-Dose Dual VS Levofloxacin Concomitant
This is a randomized controlled trial comparing the efficacy and safety of two vonoprazan-based regimens: high-dose dual therapy (vonoprazan plus a single antibiotic) versus triple therapy (vonoprazan plus two antibiotics) for…
- Conditions
- Helicobacter Pylori Infection, Peptic Ulcer Disease, Gastritis
- Trial name
- NCT07624422
- Testing
- Vonoprazan, Levofloxacin 500mg
- Where
- Syria
- Volunteers
- 150 people
- Sponsor
- Damascus Hospital
Helicobacter Pylori Infection
Effectiveness of Once-daily Dose Regimen of 7-day and 14-day High Dose Rabeprazole-levofloxacin Based Quadruple Therapy for H. Pylori Eradication in Thai Patients With Non-ulcer Dyspepsia
H.pylori is an organism which causes gastric inflammation, peptic ulcer disease (PUD), mucosa associated lymphoid tissue (MALT) lymphoma and gastric cancer.
- Trial name
- NCT03397680
- Testing
- 13C Urea Breath Test
- Where
- Thailand
- Volunteers
- 100 people
- Sponsor
- Thammasat University